Nightstar Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa
01 October 2018 - 8:05PM
Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene
therapy company developing treatments for rare inherited retinal
diseases, today announced that the company plans on presenting at
the Cell & Gene Meeting on the Mesa organized by the Alliance
for Regenerative Medicine and the Sanford Stem Cell Clinical Center
at UC San Diego, on Wednesday October 3, 2018 at 5:15pm PDT in La
Jolla, California.
To access the live webcast, please visit ir.nightstartx.com. A
replay of the webcast will be available on the Nightstar website
for two weeks following the conference.
About NightstarNightstar is a leading
clinical-stage gene therapy company focused on developing and
commercializing novel one-time treatments for patients suffering
from rare inherited retinal diseases that would otherwise progress
to blindness. Nightstar’s lead product candidate, NSR-REP1, is
currently in Phase 3 development for the treatment of patients with
choroideremia, a rare, degenerative, genetic retinal disorder that
has no current treatments. Results from a Phase 1/2 trial of
NSR-REP1 were published in The Lancet in 2014 and in The New
England Journal of Medicine in 2016. Nightstar’s second product
candidate, NSR-RPGR, is currently being evaluated in a Phase 1/2
clinical trial for the treatment of patients with X-linked
retinitis pigmentosa, an inherited X-linked recessive retinal
disease.
For more information about Nightstar or its clinical trials,
please visit www.nightstartx.com.
Contact:Senthil Sundaram, Chief Financial
OfficerBrian Luque, Sr. Manager, Investor
Relationsinvestors@nightstartx.com
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Nightstar Therapeutics Plc ADS (NASDAQ): 0 recent articles
More News Articles